The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial
Astrup A, Breum L, Toubro S, Hein P, Quaade F
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 107 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1992-04-01 · Int J Obes Relat Metab Disord · vol. 16 · número 4 · págs. 269–77
- Editorial
- National Institutes of Health
- Citado
- 227 citas · más que el 96% de estudios similares · 4.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Pharmacology and Obesity Treatment · Coffee research and impacts · Regulation of Appetite and Obesity
- Palabras clave
- ephedrine, caffeine, obesity, weight loss, hypocaloric diet, thermogenesis, sympathomimetic drugs, drug synergy, adverse effects, blood pressure
- MeSH
- humans, obesity, weight loss, ephedrine, caffeine, tablets, drug combinations, chemotherapy, adjuvant, diet, reducing, administration, oral, analysis of variance, double-blind method, energy intake, blood pressure, heart rate, drug synergism, adult, middle aged, female, male
5 autores
- Arne Vernon Astrup
- Leif Breum
- Sren Toubro
- P Hein
- FLEMMING QUAADE
Resumen
El texto original del estudio, en el idioma en que se publicó.
The sympathomimetic agent ephedrine has potent thermogenic and anti-obesity properties in rodents. The effect is markedly enhanced by caffeine, while caffeine given alone has no effect. This study was undertaken to find out if a similar weight reducing synergism between ephedrine and caffeine is present in obese patients. In a randomized, placebo-controlled, double blind study, 180 obese patients were treated by diet (4.2 MJ/day) and either an ephedrine/caffeine combination (20mg/200mg), ephedrine (20 mg), caffeine (200 mg) or placebo three times a day for 24 weeks. Withdrawals were distributed equally in the four groups, and 141 patients completed the trial. Mean weight losses was significantly greater with the combination than with placebo from week 8 to week 24 (ephedrine/caffeine, 16.6 +/- 6.8 kg vs. placebo, 13.2 +/- 6.6 kg (mean +/- s.d.), P = 0.0015). Weight loss in both the ephedrine and the caffeine groups was similar to that of the placebo group. Side effects (tremor, insomnia and dizziness) were transient and after eight weeks of treatment they had reached placebo levels. Systolic and diastolic blood pressure fell similarly in all four groups. We conclude, that in analogy with animal studies, the ephedrine/caffeine combination is effective, while caffeine and ephedrine separately are ineffective for the treatment of human obesity.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.